Effect of Cabergoline Added to Metformin on Glycemic Control, Insulin Resistance and Beta Cell Function in Obese Type 2 Diabetic Patients

Effect of Cabergoline Added to Metformin on Glycemic Control, Insulin Resistance and Beta Cell Function in Obese Type 2 Diabetic Patients

Hayder Ch. Assad

Contact

Hamoudi A. Mosah

Contact

Hashim M. Hashim

Contact

Faris A. Khazaal

Contact

α University of Kufa

Effect of Cabergoline Added to Metformin on Glycemic Control, Insulin Resistance and Beta Cell Function in Obese Type 2 Diabetic Patients

Article Fingerprint

ReserarchID

PDDTM2E4K4

Effect of Cabergoline Added to Metformin on Glycemic Control, Insulin Resistance and Beta Cell Function in Obese Type 2 Diabetic Patients Banner

AI TAKEAWAY

Connecting with the Eternal Ground

Abstract

The aim of this study is to examine the effect of cabergoline added to metformin on glycemic control, insulin resistance and B-cell function in obese type 2 diabetic patients. Forty obese patients with newly diagnosed type2 diabetes were enrolled in this study and randomized by 1:1 ratio into group (I) receives metformin and group (II) receives metformin plus cabergoline for 12 week. We evaluated fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) every 4 week while body weight, glycosylated hemoglobin, fasting plasma insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and B-cell function (HOMA-B) at the baseline and after 12 week.

References

34 Cites in Article

Reference Format

Y Lin,Z Sun (2010). Current views on type 2 diabetes.
A Astrup,N Finer (2000). Redefining Type 2 diabetes: ‘Diabesity’ or ‘Obesity Dependent Diabetes Mellitus’?.
Lalita Khaodhiar,Sue Cummings,Caroline Apovian (2009). Treating diabetes and prediabetes by focusing on obesity management.
R Defronzo (2009). From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.
H Pijl (2003). Reduced dopaminergic tone in hypothalamic neural circuits: expression of a ''thrifty''genotype underlying the metabolic syndrome.
A Tschoner,J Engl,M Laimer,S Kaser,M Rettenbacher,W Fleischhacker,J Patsch,C Ebenbichler (2007). Metabolic side effects of antipsychotic medication.
G Wang,N Volkow,P Thanos (2009). Brain Dopamine Pathways and Obesity.
U Pagotto (2009). Where Does Insulin Resistance Start? The brain.
Sudarshana Purkayastha,Dongsheng Cai (2013). Neuroinflammatory basis of metabolic syndrome.
R Scranton,M Ezrokhi,J Gaziano (2008). Randomized Pilot Study of Cabergoline, a Dopamine Receptor Agonist: Effects on Body Weight and Glucose Tolerance in Obese Adults Diabetes.
S Inancli,A Usluogullari,Ustu (2013). Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.
Ranganath Muniyappa,Sihoon Lee,Hui Chen,Michael Quon (2008). Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage.
S Taghavi,S Fatemi,H Rokni (2012). Cabergoline Effect on Blood Sugar in Type 2 Diabetic Patients with Oral Agent Failure.
P Kok,F Roelfsema,M Frolich (2006). Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women.
N Merican,N Sukor,A Razali (2013). The Effects of Short Term Cabergoline Therapy on Disease Activity and Metabolic Parameters in Acromegaly.
Alessandro Ciresi,Marco Amato,Valentina Guarnotta,Flavia Lo Castro,Carla Giordano (2013). Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Krysiak Rand Okopien,B (2014). Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels.
A Cincotta,A Meier,M Cincotta (1999). Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes.
A Ghosh,N Sengupta,P Sahana (2014). Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial.
K Bina,A Cincotta (2000). Figure 2. Glucose-lowering therapy used by patients with primary hyperparathyroidism and diabetes mellitus type 2 (people): metformin — 13; dipeptidyl-peptidase 4 inhibitors (DPP4i) — 2; combination of metformin and DPP4i — 5; combination of metformin and glucagon-like peptide 1 receptor agonists — 1; combination of metformin and sodium-glucose transporter 2 inhibitors (SGLT2i) — 2; sulfonylurea compounds — 1; combination of metformin and sulfonylurea — 2; комбинация combination of metformin, sulfonylurea and SGLT2i — 1; combination of metformin, sulfonylurea and long-acting insulin — 1; combination of metformin, SGLT2i and short-acting insulin — 2; intensive insulin therapy — 4..
Yin Liang,Maggie Lubkin,Hong Sheng,Piotrw. Scislowski,Anthony Cincotta (1998). Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice.
R Turner,A Rudenski,D Matthews (1990). Application of structural model of glucoseinsulin relations to assess beta-cell function and insulin sensitivity.
Tara Wallace,Jonathan Levy,David Matthews (2004). Use and Abuse of HOMA Modeling.
K Berinder,T Nystrom,C Hoybye (2011). Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
Dos Santos Silva,C Barbosa,F Lima,G (2011). BMI and Metabolic Profile in Patients with Prolactinoma before and After Treatment with Dopamine Agonists.
Michael Ezrokhi,Shuqin Luo,Yelena Trubitsyna,Anthony H. Cincotta (2012). Weighted Effects of Bromocriptine Treatment on Glucose Homeostasis during Hyperglycemic versus Euglycemic Clamp Conditions in Insulin Resistant Hamsters: Bromocriptine as a Unique Postprandial Insulin Sensitizer.
Futoshi Anan,Naohiko Takahashi,Mikiko Nakagawa,Tatsuhiko Ooie,Tetsunori Saikawa,Hironobu Yoshimatsu (2005). High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients.
B Corkey (2012). Hyperinsulinemia: Cause or Consequence?.
A Ustione,D Piston,P Harris (2013). A Mini review: Dopaminergic regulation of Insulin Secretion from the Pancreatic Islet.
M Sowell,N Mukhopadhyay,P Cavazzoni (2002). Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo.
Isabel García-Tornadú,Ana Ornstein,Astrid Chamson-Reig,Michael Wheeler,David Hill,Edith Arany,Marcelo Rubinstein,Damasia Becu-Villalobos (2010). Disruption of the Dopamine D2 Receptor Impairs Insulin Secretion and Causes Glucose Intolerance.
R Brown,Ki Rother,R Pivonello,De Martino,C Cappabianca,P (2008). The Medical Treatment of Cushing's disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery.
Mariano Galdiero,Renata Auriemma,Pasquale Vitale,Fabio Calzo,Ciro Salzano,Lucia Ferreri,Federica Cariati,Giorgio Coppola,Annamaria Colao,Rosario Pivonello (2014). Effect of chronic treatment with cabergoline and testosterone replacement on metabolic parameters in male patients with prolactinomas and hypogonadism.
K Sung,G Reaven,Kim Sh (2010). Utility of Homeostasis Model Assessment of B-Cell Function in Predicting Diabetes in 12,924 Healthy Koreans.

Download References

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Hayder Ch. Assad. 2014. \u201cEffect of Cabergoline Added to Metformin on Glycemic Control, Insulin Resistance and Beta Cell Function in Obese Type 2 Diabetic Patients\u201d. Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine GJMR-B Volume 14 (GJMR Volume 14 Issue B5): .

More Citation Formats

Select Citation Style:

Download Citation

Download Article

GJMR Volume 14 Issue B5
Pg. 25- 31

Explore Journals Explore Volume Read This Issue

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords

beta-cell function cabergoline glycemic control insulin resistance Obesity Type 2 diabetes

Submission ReceivedDecember 15, 2013
Peer Review Double Blind
Handling Editor
Accepted January 4, 2014
Published January 15, 2014

Version of record

v1.2

Issue date

October 25, 2014

Language

Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

View in VR

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

View in 3D

Article Matrices

Total Score: 104

Country: Iraq

Subject: Global Journal of Medical Research - B: Pharma, Drug Discovery, Toxicology & Medicine

Authors: Hayder Ch. Assad, Hamoudi A. Mosah, Hashim M. Hashim, Faris A. Khazaal (PhD/Dr. count: 0)

View Count (all-time): 171

Total Views (Real + Logic): 4497

Total Downloads (simulated): 2236

Publish Date: 2014 10, Sat

Monthly Totals (Real + Logic):

Month 1: 39 views
Month 2: 28 views
Month 3: 47 views
Month 4: 59 views
Month 5: 39 views
Month 6: 26 views
Month 7: 34 views
Month 8: 27 views
Month 9: 24 views
Month 10: 27 views
Month 11: 53 views
Month 12: 23 views
Month 13: 24 views
Month 14: 31 views
Month 15: 30 views
Month 16: 33 views
Month 17: 19 views
Month 18: 38 views
Month 19: 35 views
Month 20: 30 views
Month 21: 45 views
Month 22: 26 views
Month 23: 17 views
Month 24: 36 views
Month 25: 39 views
Month 26: 34 views
Month 27: 22 views
Month 28: 32 views
Month 29: 27 views
Month 30: 14 views
Month 31: 35 views
Month 32: 36 views
Month 33: 41 views
Month 34: 31 views
Month 35: 30 views
Month 36: 33 views
Month 37: 12 views
Month 38: 34 views
Month 39: 22 views
Month 40: 18 views
Month 41: 34 views
Month 42: 33 views
Month 43: 30 views
Month 44: 32 views
Month 45: 35 views
Month 46: 29 views
Month 47: 20 views
Month 48: 33 views
Month 49: 21 views
Month 50: 24 views
Month 51: 41 views
Month 52: 29 views
Month 53: 45 views
Month 54: 43 views
Month 55: 24 views
Month 56: 26 views
Month 57: 38 views
Month 58: 41 views
Month 59: 35 views
Month 60: 14 views
Month 61: 40 views
Month 62: 39 views
Month 63: 39 views
Month 64: 20 views
Month 65: 28 views
Month 66: 27 views
Month 67: 36 views
Month 68: 30 views
Month 69: 10 views
Month 70: 38 views
Month 71: 30 views
Month 72: 36 views
Month 73: 31 views
Month 74: 37 views
Month 75: 22 views
Month 76: 48 views
Month 77: 35 views
Month 78: 22 views
Month 79: 36 views
Month 80: 24 views
Month 81: 40 views
Month 82: 24 views
Month 83: 20 views
Month 84: 28 views
Month 85: 22 views
Month 86: 17 views
Month 87: 29 views
Month 88: 39 views
Month 89: 35 views
Month 90: 25 views
Month 91: 25 views
Month 92: 20 views
Month 93: 32 views
Month 94: 10 views
Month 95: 32 views
Month 96: 20 views
Month 97: 40 views
Month 98: 27 views
Month 99: 45 views
Month 100: 30 views
Month 101: 34 views
Month 102: 28 views
Month 103: 22 views
Month 104: 43 views
Month 105: 18 views
Month 106: 37 views
Month 107: 11 views
Month 108: 36 views
Month 109: 41 views
Month 110: 34 views
Month 111: 39 views
Month 112: 11 views
Month 113: 42 views
Month 114: 43 views
Month 115: 45 views
Month 116: 41 views
Month 117: 46 views
Month 118: 31 views
Month 119: 28 views
Month 120: 27 views
Month 121: 29 views
Month 122: 26 views
Month 123: 37 views
Month 124: 30 views
Month 125: 31 views
Month 126: 31 views
Month 127: 21 views
Month 128: 36 views
Month 129: 24 views
Month 130: 39 views
Month 131: 18 views
Month 132: 38 views
Month 133: 31 views
Month 134: 39 views
Month 135: 41 views
Month 136: 35 views
Month 137: 66 views
Month 138: 66 views
Month 139: 25 views

Total Views: 4497

Total Downloads: 2236

2026 Trends

Published Article

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]